Ascentage Pharma at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Ascentage Pharma brings 1 presentation to ASH 2026 in New Orleans, and exhibits at Booth 1957. Its research centres on lymphoma drug combinations in preclinical models. It covers an EED inhibitor that works alongside the BCL-2 inhibitor lisaftoclax.
| Organization | ASH 2026 Attendance |
|---|---|
Ascentage Pharma Suzhou, China | |
Biopharmaceutical company developing hematology drugs including olverembatinib, a third-generation TKI, and lisaftoclax, a Bcl-2 inhibitor. | Booth Exhibiting at Booth 1957 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm |
Find decision makers at Ascentage Pharma
Tell us what you sell and we’ll find the people at Ascentage Pharma most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction